These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 31043832)

  • 1. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
    Owen C; Berinstein NL; Christofides A; Sehn LH
    Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
    Bond DA; Alinari L; Maddocks K
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
    Rule S; Chen RW
    Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.
    De SK
    Curr Med Chem; 2024; 31(30):4757-4762. PubMed ID: 37818564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma.
    Morabito F; Recchia AG; Vigna E; Botta C; Skafi M; Abu-Rayyan M; Atrash M; Galimberti S; Morabito L; Al-Janazreh H; Martino M; Cutrona G; Gentile M
    Expert Opin Pharmacother; 2020 Jan; 21(1):29-38. PubMed ID: 31738609
    [No Abstract]   [Full Text] [Related]  

  • 6. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
    Eyre TA; Shah NN; Dreyling M; Jurczak W; Wang Y; Cheah CY; Song Y; Gandhi M; Chay C; Sharman J; Andorsky DJ; Messersmith HM; Ruppert AS; Muthig VA; Ito R; Wang ML
    Future Oncol; 2022 Nov; 18(36):3961-3969. PubMed ID: 36377973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
    Wang JF; Wang Y
    Expert Rev Hematol; 2024 Oct; 17(10):651-659. PubMed ID: 39109468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
    Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acalabrutinib for adults with mantle cell lymphoma.
    Jurczak W; Długosz-Danecka M; Wang M
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):179-187. PubMed ID: 30638402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dismantling relapsed/refractory mantle cell lymphoma.
    Ryan CE; Kumar A
    Blood Rev; 2024 Sep; 67():101221. PubMed ID: 38906740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
    Bond DA; Maddocks KJ
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):903-921. PubMed ID: 32861286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of acalabrutinib in patients with mantle cell lymphoma.
    Awan FT; Jurczak W
    Expert Rev Hematol; 2018 Jun; 11(6):495-502. PubMed ID: 29737219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
    Hanna KS; Campbell M; Husak A; Sturm S
    J Oncol Pharm Pract; 2020 Jul; 26(5):1190-1199. PubMed ID: 32279595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma.
    Weaver AN; Jimeno A
    Drugs Today (Barc); 2020 Aug; 56(8):531-539. PubMed ID: 33025948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Danilov AV; Persky DO
    Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
    Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL
    Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
    Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Elstrom R; Huang J; Novotny W; Wei R; Zhu J
    Clin Cancer Res; 2020 Aug; 26(16):4216-4224. PubMed ID: 32461234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapies for relapsed/refractory mantle cell lymphoma.
    Arora PC; Portell CA
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
    Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
    Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.